Could a smarter hormone schedule keep prostate cancer in check longer?
NCT ID NCT06734130
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new approach for men with stage IV prostate cancer that still responds to hormone therapy. Instead of continuous hormone treatment, doctors adjust the timing based on PSA levels and add chemotherapy. The goal is to see if this strategy can keep the cancer sensitive to hormones for at least 3 years. The study involves 25 participants and is currently active but not recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Caner Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo slow advanced prostate cancer?
- Immunotherapy and hormone combo aims to tackle incurable prostate cancer
- Smart scans may slash radiation doses for metastatic prostate cancer
- New drug cocktail shows promise for tough prostate cancer
- Vaccine-Chemo combo shows promise against spread prostate cancer
- New hope for aggressive prostate cancer: carboplatin combo tested in phase 3 trial